Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Abstract Cancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cell lung cancer. Programmed death receptor-1/programmed death receptor ligand-1 (PD-1/PD-L1) and cytotoxic T lymphocyte-as...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Weishi Cheng, Kai Kang, Ailin Zhao, Yijun Wu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2024-07-01
Edice:	Journal of Hematology & Oncology
Témata:	Lung cancer Immune checkpoint inhibitor Bispecific antibody Combination therapy Biomarker
On-line přístup:	https://doi.org/10.1186/s13045-024-01581-2
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!